Compare NAKA & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAKA | MDWD |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.1M | 181.1M |
| IPO Year | 2023 | 2013 |
| Metric | NAKA | MDWD |
|---|---|---|
| Price | $9.97 | $13.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $0.75 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 207.4K | 104.0K |
| Earning Date | 05-20-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,514.38 | $48.92 |
| Revenue Next Year | $48.27 | $35.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $12.52 |
| 52 Week High | $10.27 | $20.03 |
| Indicator | NAKA | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 70.27 | 54.73 |
| Support Level | $0.24 | $13.80 |
| Resistance Level | N/A | $14.07 |
| Average True Range (ATR) | 0.60 | 0.53 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 90.41 | 80.36 |
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets. The firm has two principal business segments: Bitcoin Operations, which houses its Bitcoin treasury and is utilized to support investments in other Bitcoin-related companies; Healthcare Operations, which provides a patient-focused healthcare experience that provides patients personalized solutions in order to reduce opioid use and improve health outcomes. The company generates the majority of its revenue from the Healthcare Operations.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.